Hyperthermia is indicated for use alone or in conjunction with radiation therapy in the palliative management of certain solid surface and subsurface malignant tumors (i.e., melanoma, squamous- or basal-cell carcinoma, adenocarcinoma, or sarcoma) that are progressive or recurrent despite conventional therapy.

Clinical studies using BSD's hyperthermia systems to deliver hyperthermia in conjunction with radiation therapy have shown that 83.7% of patients had some tumor regression, 37.4% of patients had a complete tumor regression and 24.5% had a greater than 50% tumor regression. Clinical data obtained in BSD's studies on hyperthermia and radiation therapy demonstrated that approximately 10% of patients experienced burns and blistering from heating, 8% experienced pain, 4% experienced ulceration from rapid tumor necrosis, and 2% experienced ulceration from placement of temperature sensors and rapid tumor necrosis.*